Stryker announced that it has executed a binding offer to Menix to acquire SERF SAS, a France-based joint replacement company. This acquisition would complement Stryker’s existing presence in France and across Europe as well as its global joint replacement portfolio, allowing Stryker to serve a wider range of patients. In accordance with French law, the execution of any binding agreement would occur after the works council information-consultation process has been completed. The proposed acquisition is expected to close during the first quarter of 2024, subject to customary closing conditions, including regulatory approvals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SYK:
- Stryker announces intent to acquire SERF SAS, enhancing its global joint replacement leadership
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Stryker intends to nominate Rachel Ruggeri for board of directors
- Stryker director Srikant Datar to retire
- Stryker announces Dr. Srikant Datar will retire from Board of Directors